NeuroInsights Neurotech Index soared 21% in January boosted by big gains from Amarin (AMRN), Somaxon (SOMX), Boston Life Sciences (BLSI), Cortex (COR), Renovis (RNVS), Pain Therapeutics (PTIE) and Acadia (ACAD). Amarin Corporation (AMRN) stock jumped over 150% to $3.43 per share after announcing licensing of its drug LAX-202 for fatigue associated with multiple sclerosis to Multicell Technologies Inc. (MCET) (see story, page 4). Somaxon Pharmaceuticals Inc. (SOMX), the featured company this month in Neurotech Insights, was up over 90% as investors began to take note of its successful IPO last month (see story, page 7). Boston Life Sciences (BLSI), which joined NeuroInsights recommended portfolio in October, also showed large gains this month as investors noticed the bargain valuation, still fairly low for a company with a late stage Parkinson’s diagnostic, a potential ADHD diagnostic, and several preclinical therapeutic leads. Cephalon (CEPH), which was featured in the December issue of Neurotech Insights, continued to dominate the news signing yet another settlement with a generic challenger to their fatigue treatment Provigil and announcing a delay in final FDA action on their ADHD treatment Sparlon. Acadia (ACAD), recommended in the September issue of Neurotech Insights was highlighted by Jim Cramer’s Mad Money who said the stock could go as high as $50 per share…
